Indication
triple negative breast neoplasms
1 clinical trial
2 products
Product
TAK-659Clinical trial
A Phase 1b Study to Evaluate TAK-659 in Combination With Nivolumab in Patients With Advanced Solid TumorsStatus: Terminated, Estimated PCD: 2018-11-30
Product
Nivolumab